DK3796896T3 - Farmaceutisk adrenalinformulering - Google Patents

Farmaceutisk adrenalinformulering

Info

Publication number
DK3796896T3
DK3796896T3 DK19726391.6T DK19726391T DK3796896T3 DK 3796896 T3 DK3796896 T3 DK 3796896T3 DK 19726391 T DK19726391 T DK 19726391T DK 3796896 T3 DK3796896 T3 DK 3796896T3
Authority
DK
Denmark
Prior art keywords
adrenaline
formulation
pharmaceutical
pharmaceutical adrenaline
adrenaline formulation
Prior art date
Application number
DK19726391.6T
Other languages
English (en)
Inventor
Scott Boyer
Fredrik Hübinette
Leif Ingemarsson
Shengzhen Cai
Original Assignee
Klaria Pharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding Ab filed Critical Klaria Pharma Holding Ab
Application granted granted Critical
Publication of DK3796896T3 publication Critical patent/DK3796896T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19726391.6T 2018-05-23 2019-05-23 Farmaceutisk adrenalinformulering DK3796896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808462.4A GB201808462D0 (en) 2018-05-23 2018-05-23 Pharmaceutical formulation
PCT/EP2019/063376 WO2019224323A1 (en) 2018-05-23 2019-05-23 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DK3796896T3 true DK3796896T3 (da) 2026-03-30

Family

ID=62812324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19726391.6T DK3796896T3 (da) 2018-05-23 2019-05-23 Farmaceutisk adrenalinformulering

Country Status (15)

Country Link
US (2) US12005140B2 (da)
EP (1) EP3796896B1 (da)
JP (2) JP7419263B2 (da)
KR (1) KR20210031857A (da)
CN (1) CN112236133B (da)
AU (1) AU2019274772B2 (da)
BR (1) BR112020023741A2 (da)
CA (1) CA3098112A1 (da)
DK (1) DK3796896T3 (da)
FI (1) FI3796896T3 (da)
GB (1) GB201808462D0 (da)
IL (1) IL278927B2 (da)
MA (1) MA52704A (da)
MX (1) MX2020012336A (da)
WO (1) WO2019224323A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
EP4302751A1 (en) * 2022-07-07 2024-01-10 LTS Lohmann Therapie-Systeme AG Oral thin films with low water activity
EP4302750A1 (en) * 2022-07-07 2024-01-10 LTS Lohmann Therapie-Systeme AG Oral thin films comprising adrenaline
CN115950999B (zh) * 2022-12-21 2024-08-30 武汉嘉诺康医药技术有限公司 一种同时检测重酒石酸去甲肾上腺素中api游离碱与配对有机酸的hplc检测方法
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933462A (en) * 1958-12-17 1963-08-08 Simone Marie Antoinette Radouc Improvements in or relating to the treatment of meat
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
AU3693397A (en) 1996-07-10 1998-02-02 Novartis Consumer Health S.A. Oral pharmaceutical combinations of antihistaminic compounds and terpenoids
ZA976189B (en) 1996-07-12 1999-01-11 Novartis Consumer Health Sa Oral pharmaceutical combinations
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20040247649A1 (en) 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
MXPA04011808A (es) 2002-05-31 2005-09-12 Univ Mississippi Liberacion transmucosica de canabinoides.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB0217382D0 (en) 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
KR101170844B1 (ko) 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
EP1648362A4 (en) 2003-07-01 2012-01-11 Todd Maibach THERAPEUTIC AGENTS WITH FILM
KR20050048056A (ko) 2003-11-18 2005-05-24 (주)케이비피 경구용 소모 필름 조성물
US7309387B2 (en) 2004-08-20 2007-12-18 The Dial Corporation Methods and apparatus for a low-profile air purifier
DK2486942T3 (da) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc Sammensætninger, der omfatter azelastin og fremgangsmåder til anvendelse deraf
US20060217308A1 (en) 2005-03-10 2006-09-28 Pascale Cossart Compositions for the treatment of tumor pathologies, comprising internalin B (ln1B) of Listeria monocytogene protein or a fragment thereof
WO2006096914A1 (en) * 2005-03-15 2006-09-21 Animal Ethics Pty Ltd A topical analgesic composition
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101081218A (zh) 2006-06-02 2007-12-05 范敏华 一种口腔速崩膜及其制备方法
US20070293580A1 (en) 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
KR100855566B1 (ko) 2006-09-12 2008-09-03 (주) 아모젠 경구용 소모성 필름
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
CN101594778A (zh) * 2006-12-11 2009-12-02 凯姆制药公司 苯丙胺的非标准氨基酸结合物及其制备和使用的方法
CN101668512A (zh) 2007-01-31 2010-03-10 新泽西鲁特格斯州立大学 皮肤中活性物质的控制释放
US20100215774A1 (en) 2007-02-09 2010-08-26 Todd Maibach Film comprising nitroglycerin
US20090246273A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
WO2009126132A1 (en) 2008-03-31 2009-10-15 Mark Rosenberg Formulations and methods for modulating satiety
BRPI0918253A2 (pt) 2008-09-12 2015-12-15 Critical Pharmaceuticals Ltd aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele
US8900634B2 (en) 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
NO2405942T3 (da) * 2009-03-13 2018-03-31
CN101574330A (zh) 2009-06-12 2009-11-11 上海现代药物制剂工程研究中心有限公司 苯甲酸利扎曲普坦膜剂
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
EP2480197B1 (en) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
TR201902233T4 (tr) * 2009-10-30 2019-03-21 Ix Biopharma Ltd Hızlı çözünen katı dozaj formu.
KR101077468B1 (ko) * 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR101303479B1 (ko) * 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
WO2013019187A1 (en) * 2011-07-29 2013-02-07 Kempharm, Inc. Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
EP2753321B1 (en) 2011-10-21 2021-12-15 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
JP6412492B2 (ja) * 2012-03-27 2018-10-24 ニコチーノ・アクチボラグ ニコチン製剤
WO2013171146A1 (en) 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CN102871984B (zh) 2012-11-05 2015-11-11 天津市聚星康华医药科技有限公司 一种盐酸去氧肾上腺素口腔速溶膜及其制备方法
CN102961365B (zh) * 2012-12-17 2016-01-20 天津市聚星康华医药科技有限公司 硫酸特布他林口腔速溶膜及其制备方法
WO2014137189A1 (ko) 2013-03-07 2014-09-12 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
CN105283170B (zh) 2013-06-17 2019-10-18 弗里蒙特集团有限公司 包含肾上腺素和柠檬酸的可注射的药物组合物
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015074663A1 (en) * 2013-11-19 2015-05-28 Rigshospitalet Injectable pharmaceutical compositions comprising iloprost
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
EP3131531B1 (en) 2014-04-15 2022-04-06 Propella Therapeutics, Inc. Topical compositions for pain relief, manufacture and use
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
EP3154533A4 (en) 2014-06-16 2018-01-10 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
HUE041705T2 (hu) 2014-07-31 2019-05-28 Pharmathen Sa Enalaprilt tartalmazó, szájban diszpergálódó film készítmény magas vérnyomás kezelésére gyermek populációban
WO2016024008A1 (en) 2014-08-14 2016-02-18 Helmholtz-Zentrum für Infektionsforschung GmbH Methods and compositions of carrier systems for the purpose of intracellular drug targeting
CN105878171A (zh) 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
WO2016161537A1 (en) 2015-04-08 2016-10-13 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granistron
EP3307280B1 (en) 2015-06-11 2021-10-27 Rejoy Treatment of sexual dysfunction
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CA2994331C (en) 2015-07-31 2023-10-03 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
US20170079907A1 (en) 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US9833461B2 (en) 2015-10-23 2017-12-05 Ctt Pharma Inc. Therapeutic compositions comprising cannabidiol and corticosteroids
ES2949053T3 (es) 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
WO2017135195A1 (ja) * 2016-02-03 2017-08-10 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
US10265362B2 (en) 2016-04-12 2019-04-23 Scott Schaneville Ingestible films having substances from hemp or cannabis
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US20180125977A1 (en) 2016-05-05 2018-05-10 Monosol Rx, Llc Enhanced delivery epinephrine compositions
EP3452024A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) * 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US20190350881A1 (en) * 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
CN107080745A (zh) 2017-04-14 2017-08-22 宁夏医科大学 一种载叶黄素白蛋白纳米粒的口腔速溶膜及其制备方法
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201807942D0 (en) 2018-05-16 2018-06-27 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
IL292534A (en) 2019-11-04 2022-06-01 Maabarot Products Ltd Orally administrable films comprising poorly water soluble active ingredients and preparation thereof

Also Published As

Publication number Publication date
FI3796896T3 (fi) 2026-03-26
CN112236133A (zh) 2021-01-15
JP2021526519A (ja) 2021-10-07
IL278927A (en) 2021-01-31
MX2020012336A (es) 2021-01-29
EP3796896B1 (en) 2025-12-31
EP3796896A1 (en) 2021-03-31
MA52704A (fr) 2021-03-31
IL278927B2 (en) 2025-01-01
JP7419263B2 (ja) 2024-01-22
CA3098112A1 (en) 2019-11-28
AU2019274772B2 (en) 2024-11-21
AU2019274772A1 (en) 2020-11-19
GB201808462D0 (en) 2018-07-11
US20210369601A1 (en) 2021-12-02
CN112236133B (zh) 2025-02-25
KR20210031857A (ko) 2021-03-23
JP2024050598A (ja) 2024-04-10
BR112020023741A2 (pt) 2021-02-09
WO2019224323A1 (en) 2019-11-28
US20250099374A1 (en) 2025-03-27
US12005140B2 (en) 2024-06-11
IL278927B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
SI3529248T1 (sl) Farmacevtske spojine
DK3655017T3 (da) Farmaceutisk sammensætning
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
DK3634377T3 (da) Farmaceutisk formulering
IL281717A (en) Antibody formulation
MA43705A (fr) Formulation pharmaceutique
DK3529240T3 (da) Farmaceutiske forbindelser
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
IL283900A (en) Pharmaceutical combinations
DK3583943T3 (da) Farmaceutisk sammensætning
DK3908321T3 (da) Farmaceutisk sammensætning
DK3728220T3 (da) Farmaceutiske forbindelser
SMT202400478T1 (it) Composizione farmaceutica
EP3646863A4 (en) PHARMACEUTICAL COMPOSITION
DK3601277T3 (da) Farmaceutisk formulering
EP3705122A4 (en) DELAYED RELEASE MEDICAL COMPOSITION
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
IL287416A (en) Topical formulation
IL280138A (en) Aerosolisable formulation
EP3590513A4 (en) DRUG
PT3949952T (pt) Composição farmacêutica
EP3836980C0 (en) FORMULATION
EP3881841A4 (en) PHARMACEUTICAL COMPOSITION
EP3616722A4 (en) PHARMACEUTICAL COMPOSITION